In the context of the Russian invasion of Ukraine and its consequences, the European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies in the European Economic Area (HMA) network have published initial guidance for sponsors of clinical trials operating in Ukraine.
Clinical trial sponsors were seeking guidance to adapt their protocols and methodology to the upheaval caused by Russian military aggression in Ukraine and to try to maintain the quality of the...